Passive smoking is the inhalation of environmental tobacco smoke (ETS) and is a risk factor for coronary heart disease (CHD). We aimed to describe the frequency of passive smoking among patients with CHD and to investigate the association between ETS exposure and smoking cessation.
Introduction
Passive smoking is the inhalation of environmental tobacco smoke (ETS) composed of the smoke exhaled by the smoker and the smoke released by the tobacco product. Sufficient evidence supports the conclusion that passive smoking is a risk factor for cardiovascular morbidity and mortality. 1 An estimated 379 000 deaths from ischaemic heart disease attributable to passive smoking occurred worldwide in 2004, including 156 400 cases in European regions. 2 Exposure to ETS increases the risk of coronary heart disease (CHD) by 25 -31% among non-smokers living with a smoking spouse, 3 -5 and ETS exposure at workplace is associated with a similar risk increment. 6 The association between passive smoking and CHD risk is non-linear and considerably increases at low doses, explaining the comparatively high risk of CHD among passive smokers when compared with active smokers. 7 The cardiovascular effects of passive smoking also negatively impact outcomes of patients who suffer from acute coronary syndroms. 8, 9 Consequently, the avoidance of ETS exposure among CHD patients has been acknowledged, together with smoking cessation, to 'improve outcomes as much or more than any single medical treatment can offer'. 10 Smoking cessation in fact is regarded as the most effective of all preventive measures among CHD patients, reducing mortality after myocardial infarction by 35% compared with continued smoking. 11 Current guidelines on cardiovascular disease prevention therefore recommend that smoking cessation should be encouraged and ETS exposure should be minimized in CHD patients. 12, 13 In general population samples, smoking restrictions at home 14 -16 and at workplace 17, 18 and the absence of ETS exposure in these locations 19 -21 have been related to higher cessation rates. Among patients with CHD, however, no prior study has evaluated the association between ETS exposure and smoking cessation. Using data of the EUROASPIRE III survey (EUROpean Action on Secondary and Primary Prevention through Intervention to Reduce Events), we aimed to describe the frequency of passive smoking in CHD patients across Europe and to investigate the association between ETS exposure and smoking cessation. We hypothesized that passive smoking may represent a barrier to smoking cessation in the high-risk group of CHD patients.
Methods

Study population
The EUROASPIRE III survey is a cross-sectional study conducted in 2006-07 among patients up to 80 years of age with CHD. Details of the study design and participant recruitment have been described in detail elsewhere. 22 Patients hospitalized for coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), acute myocardial infarction (AMI), and myocardial ischaemia were retrospectively identified from hospital records at 76 centres in 22 European regions. Trained research staff reviewed 13 935 medical records and interviewed 8966 patients using standardized methods at least 6 months and on average 15 months after hospitalization for the index event or procedure. Details on study centres and organizations are provided as Supplementary material. The study complies with the Declaration of Helsinki, local ethics committees have approved the research protocol, and informed consent has been obtained from study participants.
Information on smoking
Information on smoking was obtained using an interviewer-administered questionnaire. Patients were asked 'Have you ever smoked?' and if answered in the positive, 'For how many years in total have you smoked?', 'Were you smoking in the month prior to the hospital admission for the index event or procedure?', and 'Do you smoke now?'. If currently smoking, individuals were asked to report on the number of cigarettes, pipes, and cigars smoked per day, and smokers of all these types of tobacco were included in the study. Further, patients were asked 'Which one of the following steps (to stop smoking) did you take since the index event or procedure to reduce your risk of heart disease?' Possible answers to that question were: 'abstinence', 'reduction', 'smoking cessation clinic', 'nicotine replacement therapy', 'bupropion', and 'other'.
Carbon monoxide in breath
Carbon monoxide (CO) in breath was measured for biochemical validation of self-reported non-smoking at interview. The concentration of breath CO was recorded in parts per million (ppm) using calibrated instruments and following the manufacturer specifications (Bedfont Scientific, Model Micro 4 Smokerlyser, Kent, UK). After a 15 s breath hold, participants were asked to breathe out steadily and gently through a disposable mouthpiece connect to the monitor, emptying the lungs as much as possible. Following each CO measurement, the system was cleared for the next procedure exposing the sensor to room air.
Non-smokers, smoking cessation, and environmental tobacco smoke Non-smokers were defined as patients who reported non-smoking in the month prior to hospital admission. Smoking cessation was defined as reported non-smoking and ≤10 ppm CO in breath at interview in patients who were smoking prior to hospital admission. Consistent with prior works in the field, 23, 24 exposure to ETS was assessed by asking the following question at interview: 'In the daytime or at night, do you frequently stay in rooms where people smoke at home, at work and at other locations?'. Participants were asked to respond to this question providing separate answers for each location (yes/no). We evaluated exposure to ETS according to each location separately and constructed a composite variable of ETS exposure at any place, combining information on exposure at home, at work, and at other locations.
Covariates
We investigated socio-demographic (age at event, sex, educational level) and clinical characteristics (diagnostic group, recurrent CHD) as covariates of ETS exposure among non-smokers. Cardiac rehabilitation, Hospital Anxiety and Depression Scale (HADS), smoking duration, steps taken to stop smoking, and ETS exposures at home, at work, and at other locations were the additional covariates of smoking cessation. Four educational levels were considered: primary, secondary, intermediate, and higher education. Patients were categorized into diagnostic groups according to their index event or procedure. Recurrent CHD events were self-reported CABG, PCI, AMI, or myocardial ischaemia since hospital discharge. Information on cardiac rehabilitation was assessed at interview using the following questions: 'Were you advised to follow a cardiac prevention/rehabilitation programme within 3 months of discharge following the index event or procedure?' and 'If yes, did you attend the cardiac rehabilitation programme offered?' The HADS, a four-point Likert scale (range 0 -3) with seven items being related to anxiety and seven items to depression, was administered at interview. Item scores are added to obtain the summary scores on anxiety and depression separately. A score ,8 is considered to be in the normal range, scores 8 -10 indicate a possible disorder, and scores ≥11 a probable disorder. Smoking duration was defined as the number of years in total smoked at the time of hospitalization and categorized into quartiles. Regarding steps taken to stop smoking, we grouped patients who reported smoking cessation clinic, nicotine replacement therapy, bupropion, and other (smoking cessation aids), patients without these cessation aids, but who reported reduction (reduction only), and patients without cessation aids including those who reported abstinence (no smoking cessation aids).
Statistical analysis
Descriptive statistics present information on ETS exposure and smoking cessation among patients who were smoking prior to hospital admission. The mean percentages of ETS exposure among non-smokers and prevalence odds ratios (ORs) 25 of smoking cessation were calculated using logistic regression models with geographical regions modelled as a random effect. Differences in the mean percentages of ETS exposure were evaluated in univariable models adjusting for multiple comparisons by the Bonferroni correction. Multivariable associations of ETS exposure with smoking cessation were estimated adjusting for significant covariates Passive smoking and smoking cessation among patients with CHD identified in univariable analyses. Effect modification and association with time since hospitalization were examined. All patients for whom data were available on the variables concerned were considered in the descriptive and univariable analyses and only patients with data on all covariates entered the multivariable models. Statistical tests were two-tailed and an a-level of 0.05 was chosen to indicate statistical significance. The statistical analysis was carried out using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
In the present study, we included 8729 study participants with complete information on smoking at interview, smoking prior to hospital admission, and ETS exposure at home, at work, and at other locations. These patients were younger [mean (SD) 61.6 (9.6) vs. 64.2 (8.9) years, P , 0.001] and less frequently women (25.1 vs. 32.5%, P ¼ 0.010) than excluded patients for whom we did not have complete information (n ¼ 237; 2.6%), but similar with regard to educational level and diagnostic group. In the month prior to hospital admission, 6060 (69.4%) patients were non-smokers and 2669 (30.6%) were smokers, 1283 of whom reported non-smoking at interview and had ≤ 10 ppm CO in breath, corresponding to a frequency of smoking cessation of 48.1%.
Frequency of environmental tobacco smoke exposure
Among non-smokers, 623 (10.3%) patients were exposed to ETS at home, 437 (7.2%) at work, and 835 (13.8%) at other locations, compared with 815 (30.5%), 603 (22.6%), and 856 (32.1%) patients, respectively, exposed to ETS at home, work, and other locations among smokers. Notably, non-smokers exposed to ETS at any place (n ¼ 1468) had higher breath CO levels than those not exposed [mean (SE) 2.16 (0.10) vs. 1.51 (0.04) ppm, P , 0.001]. In Figure 1 , the Venn diagram shows the number of non-smokers with ETS exposure at home, at work, and at other locations among the 1468 (24.2%) non-smokers exposed to ETS at any place. Marked differences in the frequency of ETS exposure at any place were observed in non-smokers between geographical regions, ranging from 3.1 to 50.2% ( Figure 2 ). Table 1 presents the frequency of ETS exposure by patient characteristics among non-smokers. Exposure to ETS at home, at work, and at other locations decreased with increasing age at event. Home ETS exposure was higher in women than men (11.8 vs. 7.5%, P , 0.001) and decreased with educational level (11.0% primary vs. 6.8% higher, P ¼ 0.002). In contrast, males showed a markedly higher exposure to ETS at other locations when compared with females (11.2 vs. 6.6%, P , 0.001). ETS exposure at work was higher in men than women (6.4 vs. 3.1%, P , 0.001) and increased with educational level (3.0% primary vs. 7.7% higher, P , 0.001). Generally, ETS exposure at work followed the frequency of employment by age (68.0, 49.3, 16.1, and 5.1% at ages ,50, 50 -59, 60 -69, and 70-79 years, respectively), sex (30.5% in men, 11.1% in women), and educational level (12.8, 24.3, 24.3 , and 43.0% in primary, secondary, intermediate, and higher, respectively).
Among patients who were smoking prior to hospital admission, quitters at interview less frequently reported ETS exposure than non-quitters (16.1, 15.1, and 25.3 vs. 43.9, 29.5, and 38.3% at home, work, and other locations, respectively). Figure 3 and see Supplementary material online, Table S1 ). Table 3 shows multivariable associations of ETS exposure with smoking cessation among 2443 patients with data on all covariates. After adjustment for significant variables identified in univariable analyses, the associations of ETS at home (OR 0. Odds ratios with 95% confidence intervals and probability values from logistic regression models with geographical regions modelled as a random effect. AMI, acute myocardial infarction; CABG, coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; ETS, environmental tobacco smoke; HADS, Hospital Anxiety and Depression Scale; OR, odds ratio; PCI, percutaneous coronary intervention. Figure 3 Univariable associations of environmental tobacco smoke exposure at home, at work, and at other locations with smoking cessation among patients who were smoking prior to hospital admission by geographical region (n ¼ 2669). Odds ratios with 95% confidence intervals from univariable logistic regression models. ETS: environmental tobacco smoke.
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Discussion
The present study reports on the frequency of passive smoking in CHD patients from 22 European regions and the association between ETS exposure and smoking cessation. Overall, one-quarter of non-smokers were exposed to ETS at any place with marked differences between geographical regions. Among patients who were smoking prior to hospital admission, exposure to ETS at home and ETS exposure at work as well as at other locations decreased the likelihood of smoking cessation by 70 and 40%, respectively.
Passive smoking
Passive smoking at home, at work, and at other locations affected a noteworthy proportion of non-smokers in our study. We are not aware of any other database documenting ETS exposure among the high-risk group of CHD patients across Europe. In the general population, the European Community Respiratory Health Survey (ECRHS) has investigated ETS exposure at home and at workplace among young adults, asking whether they had regularly (most days or nights) been exposed to tobacco smoke in the past 12 months. 26 According to data of the ECRHS in 14 countries, including
Australia and the USA, the prevalence of passive smoking was 24% in 2000 -02 after declining by 18% over 10 years of follow-up (age 22 -44 years at baseline). 19 Similar to our study results, distinct variations in the prevalence of ETS exposure were observed between study regions, ranging from 6 to 65%. 19 In further agreement with our study findings, older age groups were less likely to become exposed to ETS and subjects with low educational level were both more likely to become and less likely to stop being exposed during follow-up. 19 Apart from a discontinuation of work-related passive smoking, lower ETS exposure among the elderly has been attributed to age-related lifestyle changes and smaller proportions of active smokers in older age groups. 27 Higher ETS exposure at home among female non-smokers in our study may be related to active smoking of their life partners and gender inequity in the private sphere. 28 Lower ETS exposure at work with increasing age and decreasing educational level and in females than males may, at least in part, be explained by the described differences in employment status. Higher ETS exposure at other locations among men when compared with women may arise from differential social behaviours and the higher prevalence of active smoking among males in the general population. 19 Overall, our data show higher frequencies of passive smoking in younger age groups as well as gender disparities and social differences in ETS exposure among European CHD patients.
Smoking cessation
To the best of our knowledge, this study is the first to investigate ETS exposure and smoking cessation in CHD patients, providing evidence for an adverse association in this high-risk group. With regard to other covariates of smoking cessation, the significant associations of age at event, educational level, anxiety, depression, and smoking duration in our study reflect findings of prior studies in population samples. 19 -21,29 The increased likelihood of smoking cessation among patients advised and attending cardiac rehabilitation and among patients using cessation aids concur with results of randomized controlled studies. 30 The positive association of no cessation aids with smoking cessation may be explained by quitting at the first go without aids. Population-based studies on passive smoking and smoking cessation have evaluated environmental smoke policies and self-reported ETS exposure in different locations. The effect of smoke-free workplaces on smoking behaviour has been investigated by a number of studies. 17 A recent prospective study including 1967 participants of the Community Intervention Trial for Smoking Cessation (COMMIT) demonstrated an approximately two-fold likelihood of smoking cessation among employees working in environments with smoke-free policies. 18 The association of smoke-free homes as well as home ETS exposure with smoking cessation has been studied less extensively. A cohort of 4963 participants from the COMMIT found that smokers living in smoke-free homes were 70% more likely to quit than those who allowed smoking in their homes. 16 A cross-sectional study among 48 584 US adults from three population surveys that investigated the combined effect of home and workplace smoking bans showed a 65% higher likelihood of smoking cessation for people living or working in places with such restrictions. 14 The abovementioned ECRHS observed a 55 and 31%
lower likelihood of smoking cessation among individuals exposed to ETS at home and workplace, respectively. 19 Thus, the strength of the associations between home and work ETS exposure and smoking cessation in our study resembles the effect size of smoke-free policies and ETS exposure on smoking cessation in community-based studies.
A recent study analysing representative surveys conducted in 21 countries, states, and provinces that implemented smoke-free legislations covering bars, restaurants, and work-places showed inconsistent results with regard to the impact on smoking prevalence. 31 In our study, we calculated a population-attributable fraction of non-quitting for ETS exposure at any place of 0. cross-sectional studies are suboptimal for such calculations, this estimate should be interpreted with caution.
Perspectives
In the light of the great benefit of smoking cessation in CHD patients, our study results strongly argue for addressing the avoidance of ETS exposure in quitting strategies for secondary prevention. Legislative smoking bans have been shown to effectively reduce ETS exposure in workplaces, restaurants, pubs, and public places, but appear to be ineffective in reducing exposure in the homes. 32 Ongoing and future population strategies to decrease passive smoking may, therefore, need to be paralleled with preventive measures targeting the highrisk group of CHD patients. In this regard, clinical trials should investigate specific interventions directed at the reduction in ETS exposure among non-smokers and smokers with CHD in home, workplace, and other environments.
Limitations and strengths
One important limitation of this study is its rather small study sample in the analysis on smoking cessation, leading to imprecise estimates of the associations by geographical region, manifested by wide CIs. However, multilevel modelling of these associations enabled pooled data analysis that accounts for regional variations to obtain robust study results. Another important limitation of this study is that the applied question whether patients frequently stayed in rooms where people smoke lacks information on exposure period. However, since breath CO is a useful indicator of recent ETS exposures, 1 higher CO levels in non-smokers exposed to ETS at any place suggest appropriate response validity regarding current passive smoking. No information was available on the amount of tobacco used per day in patients who quit smoking and on the use of smokeless tobacco products. As a limitation of the cross-sectional nature of our study, we cannot exclude the possibility of reverse causation bias in that quitters may have more frequently avoided environments where people smoke than continued smokers. Strengths of our study comprise the inclusion of CHD patients from 22 European regions, the standardized assessment of exposures and outcomes, and the measurement of breath CO as a biomarker to validate self-reported non-smoking at interview.
Conclusion
A noteworthy proportion of non-smokers with CHD are exposed to ETS across Europe, making the reduction in ETS exposure an important issue of secondary prevention. Passive smoking may jeopardize smoking cessation in CHD patients and needs therefore to be addressed in quitting strategies.
Supplementary material
Supplementary material is available at European Heart Journal online.
